Skip to main content
. 2012 Aug 3;70(3):451–459. doi: 10.1007/s00280-012-1938-3

Table 5.

Previous reports on gemcitabine and paclitaxel therapy after failure of cisplatin-based chemotherapy

Study year (Ref.) N Gemcitabine, Paclitaxel (mg/m2; day) (every weeks) CR/PR (%) SR 1-yr/2-yr (%) Median survival (mos) Grade 3/4 leuko-/thrombocytopenia (%)
2001 [10] 41

2,500–3,000; 1

150; 1

(2)

27.5/32.5 NS/NS 14.4 31.7/0.0
2001 [11] 15

1,000; 1, 8, 15

200; 1

(3)

6.7/40.0 NS/NS NS NS/NS
2005 [12] 36

1,000; 1, 8, 15

110; 1, 8, 15

(4)

41.7/27.8 NS/NS 15.3 36.1/8.3
2006 [13] 23

2,500; 1

150; 1

(2)

0.0/30.4 NS/NS 12.1 26.1/NS
2006 [14] 14

1,000; 1, 8

175; 1

(3)

50.0/0.0 NS/NS 13 35.7/0.0
13

1250; 1

120; 2

(2)

7.7/30.8 NS/NS 9 23.1/15.4
2007 [15] 10

1,000; 1, 8, 15

200; 1

(3)

20.0/50.0 40/NS 10.3 50.0/10.0
2008 [16] 20

2,500; 1

150; 1

(2/3)

5.0/25.0 35/NS 11.5 30.0/5.0
2009 [17] 33

1,000; 1, 8, 15

180; 1

(4)

3.0/0.0 NS/NS 11.3 18.2/NS
2011 [18] 24

1,000; 1, 8, 15

200; 1

(3)

8.3/33.3 52/11 12.4 66.7/4.2
2011 [19] 48

1,000; 1, 8

175; 1

(3a)

12.5/25.0 NS/NS 7.8 NS/NS

1000; 1, 8

175; 1

(3b)

14.6/26.8 NS/NS 8.0 NS/NS
This study 35

700; 1, 8

70; 1, 8

(4)

0.0/25.7 58.1/32.9 12.0 14.3/8.6

NS not shown, SR survival rate, yr year, mos months

aA maximum of 6 cycles; b Given until disease progression